Traditional cooling systems for buildings use refrigerants and electricity, which contribute to the atmospheric greenhouse ...
PRINCETON - PDS Biotechnology Corporation (NASDAQ:PDSB) has confirmed plans to commence its VERSATILE-003 Phase 3 clinical trial for a promising cancer immunotherapy within the first quarter of 2025.
PDS Biotechnology (PDSB) reaffirmed the Company’s guidance of initiating its VERSATILE-003 Phase 3 clinical trial of Versamune HPV plus ...
The Philippine Stock Exchange Inc. (PSE) has closed another share purchase deal with one of the shareholders of the ...